What's the patent situation for Avacta's PDCs?25 Oct 2024 15:10
Intellectual property, and the patent literature in particular, is a very complex field and the guys involved in it from those drawing up the patents through to those arguing over validity in court deserve all the money they earn.
Avacta have revealed two payloads (warheads) in their PDC program, exatecan and, I suppose, MMAE. Here are ChatGPT's responses to the question "Are specifically {warhead} (NOT derivatives of {warhead}) ADC payloads out of patent?"
Exatecan
The original compound exatecan (DX-8951f) itself, without any specific modifications or derivatives, has indeed had patents that are either expired or are nearing expiration in many jurisdictions. This can make exatecan in its base form more accessible for use as an ADC payload, depending on the exact application and any additional modifications or linkers used.
Key Points on Exatecan’s Patent Status as an ADC Payload:
1. Exatecan as a Standalone Compound:
• The earliest patents for exatecan (DX-8951f) were filed in the late 1990s and early 2000s. These core patents are likely expired or nearing expiration in major regions, including the U.S., EU, and Japan.
2. Use in ADCs:
• While exatecan itself might be out of patent, ADC formulations involving exatecan with specific linker chemistries or conjugation techniques might still be protected. Many linker technologies developed for exatecan-based ADCs are newer and are still under patent protection.
3. Derivative Compounds (e.g., DXd):
• Modified exatecan derivatives, like DXd (used in trastuzumab deruxtecan), are proprietary to companies like Daiichi Sankyo. The unique structure and linker technology make DXd derivatives patent-protected, even though unmodified exatecan may be out of patent.
Practical Application:
If you plan to use exatecan in ADC development:
• Verify Linker Patents: Standard linkers that aren’t patented may be combined with exatecan, but newer linker technologies specific to ADCs might still be restricted.
• Check Regional Patents: Patent expiration dates vary across jurisdictions, so an exatecan patent could still be active in some regions while expired in others.
For confirmation of specific expiration dates or any remaining patents on ADC applications of exatecan, consulting a patent attorney or using databases like the USPTO, Espacenet, or WIPO would be beneficial to ensure freedom to operate.
--------------- continued
Sign In
Follow the stocks
